TY - JOUR
T1 - Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility
AU - Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network
AU - Huang, Hao
AU - Kuang, Hongying
AU - Sun, Fangbai
AU - Diamond, Michael Peter
AU - Legro, Richard S.
AU - Coutifaris, Christos
AU - Alvero, Ruben
AU - Robinson, Randal D.
AU - Casson, Peter R.
AU - Christman, Gregory M.
AU - Hansen, Karl R.
AU - Santoro, Nanette
AU - Eisenberg, Esther
AU - Zhang, Heping
N1 - Funding Information:
H.H. has nothing to disclose. H.K. has nothing to disclose. F.S. has nothing to disclose. M.P.D. reports grants from the National Institute of Child Health and Human Development during the conduct of the study and grants from Obseva, Abbvie, and Bayer, outside of the submitted work. R.S.L. is a consultant for Bayer, Kindex, Odega, Millendo, Abbvie, and Ferring and is a site investigator for and has received grants from Ferring, outside of the submitted work. C.C. reports grants from the National Institute of Child Health and Human Development/National Institutes of Health during the conduct of the study. R.A. has nothing to disclose. R.D.R. reports grants from Abbvie outside the submitted work. P.R.C. has nothing to disclose. G.M.C. reports grants from the National Institutes of Health during the conduct of the study and personal fees and grants from Abbvie Pharmaceuticals, outside of the submitted work. K.R.H. reports grants from the National Institute of Child Health and Human Development/National Institutes of Health during the conduct of the study and grants from Roche Diagnostics and Ferring International Pharmascience Center US, outside of the submitted work. N.S. has nothing to disclose. E.E. has nothing to disclose. H.Z. reports grants from the National Institutes of Health during the conduct of the study.Supported by grants from the National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10 HD39005 to Dr. Diamond, U10 HD38992 to Dr. Legro, U10 HD27049 to Dr. Coutifaris, U10 HD38998 to Dr. Alvero, U10 HD055942 to Dr. Robinson, U10 HD055944 to Dr. Casson, U10 HD055936 to Dr. Christman, U10 HD055925 to Dr. Zhang, and U10 U54-HD29834 to the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core of the Specialized Cooperative Centers Program in Reproduction and Infertility Research), and the National Center for Research Resources, and the National Center for Advancing Translational Sciences (UL1 TR000127 to Pennsylvania State University), and by the American Recovery and Reinvestment Act. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. The authors acknowledge Marcelle Cedars, M.D. for her comments on this manuscript.
Funding Information:
H.H. has nothing to disclose. H.K. has nothing to disclose. F.S. has nothing to disclose. M.P.D. reports grants from the National Institute of Child Health and Human Development during the conduct of the study and grants from Obseva , Abbvie , and Bayer , outside of the submitted work. R.S.L. is a consultant for Bayer, Kindex, Odega, Millendo, Abbvie, and Ferring and is a site investigator for and has received grants from Ferring , outside of the submitted work. C.C. reports grants from the National Institute of Child Health and Human Development / National Institutes of Health during the conduct of the study. R.A. has nothing to disclose. R.D.R. reports grants from Abbvie outside the submitted work. P.R.C. has nothing to disclose. G.M.C. reports grants from the National Institutes of Health during the conduct of the study and personal fees and grants from Abbvie Pharmaceuticals, outside of the submitted work. K.R.H. reports grants from the National Institute of Child Health and Human Development / National Institutes of Health during the conduct of the study and grants from Roche Diagnostics and Ferring International Pharmascience Center US, outside of the submitted work. N.S. has nothing to disclose. E.E. has nothing to disclose. H.Z. reports grants from the National Institutes of Health during the conduct of the study.
Funding Information:
Supported by grants from the National Institutes of Health , the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10 HD39005 to Dr. Diamond, U10 HD38992 to Dr. Legro, U10 HD27049 to Dr. Coutifaris, U10 HD38998 to Dr. Alvero, U10 HD055942 to Dr. Robinson, U10 HD055944 to Dr. Casson, U10 HD055936 to Dr. Christman, U10 HD055925 to Dr. Zhang, and U10 U54-HD29834 to the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core of the Specialized Cooperative Centers Program in Reproduction and Infertility Research), and the National Center for Research Resources , and the National Center for Advancing Translational Sciences (UL1 TR000127 to Pennsylvania State University), and by the American Recovery and Reinvestment Act. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health.
Publisher Copyright:
© 2019 American Society for Reproductive Medicine
PY - 2019/5
Y1 - 2019/5
N2 - Objective: To study whether there is a difference in the prevalence of non–cavity-distorting uterine fibroids between infertile patients with polycystic ovary syndrome (PCOS) and those with unexplained infertility (UI). Design: A secondary analysis of data from three randomized clinical trials. Setting: Academic health centers. Patient(s): A total of 2,249 patients with normal uterine cavities. Interventions(s): None. Main Outcome Measure(s): The presence or absence of non–cavity-distorting fibroids. Result(s): Compared with women with UI, those with PCOS were younger, had a higher body mass index, and were more likely to be Hispanic or African American, with a lower percentage of previous conception and live birth, a higher percentage of current smokers, a lower percentage of current alcohol users, and higher total testosterone, fasting insulin, and homeostasis-model-assessment insulin resistance. The prevalence of women with non–cavity-distorting uterine fibroids was lower in women with PCOS than in those with UI (6.7% vs. 12.4%); this result held after patients were divided into Black and non-Black or into three different body mass index groups. After adjustment for all the other variables in the final model, patients with PCOS had a significantly lower prevalence of fibroids than those with UI (odds ratio 0.54). No differences in the prevalence of non–cavity-distorting fibroids with any dimensions ≥4 cm or the volume of the largest fibroid was found between the two groups. Conclusion(s): A lower prevalence of non–cavity-distorting uterine fibroids was found in infertile women with PCOS than in those with UI.
AB - Objective: To study whether there is a difference in the prevalence of non–cavity-distorting uterine fibroids between infertile patients with polycystic ovary syndrome (PCOS) and those with unexplained infertility (UI). Design: A secondary analysis of data from three randomized clinical trials. Setting: Academic health centers. Patient(s): A total of 2,249 patients with normal uterine cavities. Interventions(s): None. Main Outcome Measure(s): The presence or absence of non–cavity-distorting fibroids. Result(s): Compared with women with UI, those with PCOS were younger, had a higher body mass index, and were more likely to be Hispanic or African American, with a lower percentage of previous conception and live birth, a higher percentage of current smokers, a lower percentage of current alcohol users, and higher total testosterone, fasting insulin, and homeostasis-model-assessment insulin resistance. The prevalence of women with non–cavity-distorting uterine fibroids was lower in women with PCOS than in those with UI (6.7% vs. 12.4%); this result held after patients were divided into Black and non-Black or into three different body mass index groups. After adjustment for all the other variables in the final model, patients with PCOS had a significantly lower prevalence of fibroids than those with UI (odds ratio 0.54). No differences in the prevalence of non–cavity-distorting fibroids with any dimensions ≥4 cm or the volume of the largest fibroid was found between the two groups. Conclusion(s): A lower prevalence of non–cavity-distorting uterine fibroids was found in infertile women with PCOS than in those with UI.
KW - PCOS
KW - non–cavity-distorting fibroids
KW - risk factor
KW - unexplained infertility
UR - http://www.scopus.com/inward/record.url?scp=85063321793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063321793&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2019.01.020
DO - 10.1016/j.fertnstert.2019.01.020
M3 - Article
C2 - 30926125
AN - SCOPUS:85063321793
SN - 0015-0282
VL - 111
SP - 1011-1019.e1
JO - Fertility and sterility
JF - Fertility and sterility
IS - 5
ER -